Argenx SE (ARGX) said Wednesday that it has recruited 50% of the immune thrombocytopenia (ITP) patients in the phase 2 proof-of-concept study of ARGX-113, an investigational therapy for treatment of IgG-mediated autoimmune diseases.

The study will enroll up to 36 ITP patients with platelet levels lower than 30 million per milliliter. ARGX-113 will be dosed on top of current standard of care, including corticosteroids and/or immunomodulatory agents and/or TPO-R agonists.

The primary endpoints of the trial are safety and tolerability, and secondary endpoints are effect on platelet count and use of rescue treatment, and an assessment of pharmacokinetics and pharmacodynamic markers.

The ITP clinical trial was initiated in March 2017. ARGX-113 is also being studied in a Phase 2 proof-of-concept study for the treatment of myasthenia gravis, which was initiated in January 2017.


Fatal error: Call to undefined function printFooterForm() in /home3/boost/public_html/westoverreview.com/wp-content/themes/alpha/single.php on line 57